Zhao Anqi, Pan Chaolan, Li Ming
Department of Dermatology Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
Institute of Dermatology Shanghai Jiao Tong University School of Medicine Shanghai China.
Pediatr Investig. 2023 Sep 14;7(3):177-190. doi: 10.1002/ped4.12400. eCollection 2023 Sep.
Atopic dermatitis (AD) is a complex disease characterized by recurrent eczematous lesions and refractory pruritus that drastically impairs quality of life. Due to the chronic and relapsing course, patients are easily trapped in the debilitating condition. Classical therapies show limitations, especially for patients with moderate-to-severe phenotypes. Advanced new insights in targeted therapies exhibit great application prospects which were reinforced by the more profound understanding of the disease pathogenesis. However, the sustained efficiency, biosafety, and long-term benefits still remain in further exploration. This review summarizes recent clinical studies on oral small-molecule inhibitors and biological agents for pediatric AD patients, which provides the latest frontiers to clinicians.
特应性皮炎（AD）是一种复杂的疾病，其特征为反复出现的湿疹样皮损和难治性瘙痒，严重损害生活质量。由于病程呈慢性且易复发，患者很容易陷入虚弱状态。传统疗法存在局限性，尤其是对于中重度表型的患者。靶向治疗方面的新见解展现出了巨大的应用前景，对疾病发病机制更深入的理解进一步强化了这一点。然而，其持续疗效、生物安全性和长期益处仍有待进一步探索。本综述总结了近期针对儿童AD患者的口服小分子抑制剂和生物制剂的临床研究，为临床医生提供了最新的前沿信息。
